Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synergy Pharmaceuticals Inc.

www.synergypharma.com

Latest From Synergy Pharmaceuticals Inc.

Zelnorm's Return: US FDA Panel Hands Down Split Decision On Constipation Drug's Target Population

Seven advisory committee members said the treatment for irritable bowel syndrome with constipation should be labeled for females at low cardiovascular risk; three panelists, including two cardiologists, supported a narrower indication limited to low CV risk patients who also suffer from severe symptoms.

Advisory Committees Drug Review

On A Roll: Arena Continues Streak Of Positive Data With Small Crohn's Pain Study

Arena announced encouraging data from a small Phase IIa study for olorinab (APD371) in abdominal pain associated with Crohn's disease as the company continues a streak of good news after two of its more advanced clinical-stage programs posted positive results.

Business Strategies Clinical Trials

US FDA Reviews IBS-C Candidates Both New (Tenapanor) And Old (Tegaserod)

Ardelyx touts tenapanor's novel mechanism, favorable safety profile; advisory committee announcement reveals US Worldmeds’ bid to revive Novartis’ withdrawn Zelnorm.
Drug Review Gastrointestinal

Key Drug Launches To Plan For In 2019

Around three dozen key late-stage products could reach their first markets in 2019, according to a recent report from Informa Pharma's Biomedtracker. Company execs may need to plan for the disruptive potential of this group of new medicines on established markets and standards of care.

Approvals Launches
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Synergy Pharmaceuticals Inc.
  • Senior Management
  • Troy Hamilton, CEO
    Gary G Gemignani, EVP, CFO
    Patrick H Griffin, MD, EVP, CMO
    Marino Garcia, EVP, Chief Strategy Officer
  • Contact Info
  • Synergy Pharmaceuticals Inc.
    Phone: (212) 297-0020
    420 Lexington Ave., Ste. 2012
    New York, NY 10170
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register